The price of Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) closed at $85.68 in the last session, down -0.89% from day before closing price of $86.45. In other words, the price has decreased by -$0.89 from its previous closing price. On the day, 0.65 million shares were traded. RYTM stock price reached its highest trading level at $86.88 during the session, while it also had its lowest trading level at $84.22.
Ratios:
We take a closer look at RYTM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.13 and its Current Ratio is at 3.30. In the meantime, Its Debt-to-Equity ratio is 13.60 whereas as Long-Term Debt/Eq ratio is at 13.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Buy rating and assigned the stock a target price of $97.
On July 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $88.
BofA Securities Upgraded its Neutral to Buy on April 07, 2025, while the target price for the stock was maintained at $63.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 09 ’25 when Smith Hunter C sold 42,120 shares for $80.48 per share. The transaction valued at 3,389,756 led to the insider holds 116,915 shares of the business.
Shulman Joseph sold 7,969 shares of RYTM for $619,851 on Jul 09 ’25. The Chief Technical Officer now owns 8,509 shares after completing the transaction at $77.78 per share. On Jul 09 ’25, another insider, German Christopher Paul, who serves as the Corporate Controller & CAO of the company, sold 3,817 shares for $80.75 each. As a result, the insider received 308,217 and left with 922 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 5653945856 and an Enterprise Value of 5394328576. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.12 while its Price-to-Book (P/B) ratio in mrq is 287.13. Its current Enterprise Value per Revenue stands at 39.414 whereas that against EBITDA is -20.473.
Stock Price History:
The Beta on a monthly basis for RYTM is 2.40, which has changed by 0.7977339 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $94.80, while it has fallen to a 52-week low of $40.61. The 50-Day Moving Average of the stock is 21.77%, while the 200-Day Moving Average is calculated to be 43.04%.
Shares Statistics:
According to the various share statistics, RYTM traded on average about 722.37K shares per day over the past 3-months and 606530 shares per day over the past 10 days. A total of 63.49M shares are outstanding, with a floating share count of 60.07M. Insiders hold about 8.54% of the company’s shares, while institutions hold 92.76% stake in the company. Shares short for RYTM as of 1752537600 were 4789385 with a Short Ratio of 6.63, compared to 1749772800 on 4757385. Therefore, it implies a Short% of Shares Outstanding of 4789385 and a Short% of Float of 9.33.
